MedDataX Logo

Simvastatin in Patients With Isolated Arterial Hypertension

NCT ID: NCT01017835

Last Updated: 2009-11-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether combined therapy with simvastatin and hypotensive drugs (ACEI or ARB) may decrease the blood pressure. Moreover, we would like to assess the influence of isolated hypertension on endothelial injury, and on the development of atherosclerosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertension is one of the most important predictors of cardiovascular diseases (CVD). Due to the fact that hypertension frequently coexists with hypercholesterolemia and diabetes which increase the risk of CVDs development, it is advisable to use the optimal combined therapy (hypotensive + hypolipidemic + hypoglycemic)in this group of patients. Statins are the most effective and widely used drugs for the treatment of hypercholesterolemia. According to the available experimental and clinical data they may decrease the blood pressure (BP) in normotensive and hypertensive patients. However, it is still difficult to determine to what degree the reduction of both blood pressure and cardiovascular risk is due to hypotensive or hypolipidemic/pleiotropic effects of statins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

statins isolated hypertension atherosclerosis lipid profile

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

statin treatment, isolated hypertension

treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking

No interventions assigned to this group

placebo treatment, isolated hypertension

treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* isolated hypertension (I or II class according to ESH guidelines 2009)

Exclusion Criteria

* ischemic heart disease, prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting (CABG), heart failure, diabetes, hyperlipidemia, active smokers
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medical University of Lodz

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Departament of Hypertension

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maciej Banach, MD PhD

Role: STUDY_CHAIR

Departament of Hypertension , Medical University of Lodz

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Departament of Nephrology, Hypertension and Family Medicine, Clinical Hospital of Medical University of Lodz

Lodz, , Poland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Poland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marta Michalska, MSc

Role: CONTACT

Phone: 501154853

Email: [email protected]

Maciej Banach, MD PhD

Role: CONTACT

Phone: 604593040

Email: [email protected]

References

Explore related publications, articles, or registry entries linked to this study.

Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin. 2009 Aug;25(8):1995-2005. doi: 10.1185/03007990903098081.

Reference Type BACKGROUND
PMID: 19555312 (View on PubMed)

Rysz J, Aronow WS, Stolarek RS, Hannam S, Mikhailidis DP, Banach M. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets. 2009 May;13(5):541-50. doi: 10.1517/14728220902882130.

Reference Type BACKGROUND
PMID: 19368496 (View on PubMed)

Szadkowska I, Stanczyk A, Aronow WS, Kowalski J, Pawlicki L, Ahmed A, Banach M. Statin therapy in the elderly: a review. Arch Gerontol Geriatr. 2010 Jan-Feb;50(1):114-8. doi: 10.1016/j.archger.2008.12.012. Epub 2009 Feb 13.

Reference Type BACKGROUND
PMID: 19217673 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

503-5139-2

Identifier Type: -

Identifier Source: org_study_id